ClinicalTrials.gg
CompletedNCT03498430Updated May 19, 2021

Copanlisib Chinese PK Study

A Phase 1 interventional study of Copanlisib (Aliqopa, BAY80-6946) in Lymphoma, Non-Hodgkin, sponsored by Bayer. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Bayer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing copanlisib in Lymphoma, Non-Hodgkin — none open to participants now, 1 under way, none of them phase 3. copanlisib · Lymphoma, Non-Hodgkin.

Enrollment
9th of 13
13 · median 25
Started
2018
the only one that year
Phase 1
6 of 13
none open now
Registered
8th of 13
by date
Lead sponsor
8 of 13
Bayer

Among the 13 studies testing copanlisib in Lymphoma, Non-Hodgkin, this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 6 in phase 1, and was the 8th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

None of the 13 studies testing copanlisib in Lymphoma, Non-Hodgkin is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →

About copanlisib

copanlisib: first FDA approval 2017 (ALIQOPA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing copanlisib in Lymphoma, Non-Hodgkin as a file.
02

Study summary

This study will be conducted primarily to determine the pharmacokinetics of copanlisib in Chinese patients with relapsed iNHL.

The primary objective of the study is to determine the pharmacokinetics of copanlisib administered on Day1, 8, and 15 of a 28-days cycle (3 weeks-on/1 week off dosing regimen) as a 1 hour intravenous infusion to Chinese patients with relapsed iNHL.

The secondary objectives include the evaluation of safety, tolerability, and tumor response of Chinese patients treated with Copanlisib.

Determine the pharmacokinetics of M-1 metabolite.

03

Conditions studied

  • Lymphoma, Non-Hodgkin

Keywords

  • Indolent Non-Hodgkin's Lymphoma (iNHL) (excluding CLL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and to sign an form. The informed consent must be signed before any study specific tests or procedures are done
  • Chinese, age ≥ 18 years
  • Patients with confirmed indolent NHL (excluding chronic lymphocytic leukemia) that have and who are without past or current central nervous system involvement.
  • Patients must have at least 1 according to the Lugano Classification.

    • Patients affected by LPL/WM must have also measurable disease, defined as presence of IgM paraprotein with a minimum IgM level of equal to or greater than 2 times the (ULN) OR over 10% of lymphoplasmacytic cells in bone marrow.
    • Patients with splenic MZL with splenomegaly but no measurable lesion will be considered eligible.
  • (ECOG) Performance Status of 0 or 1
  • of at least 12 weeks
  • (LVEF) ≥ 50%
  • (PT) or international normalized ratio (INR) and activated partial thromboplastin time (aPTT) \< 1.5 x the upper limit of normal (ULN)
  • Adequate bone marrow, liver and renal function
  • Women of must have a pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment
  • Women of childbearing potential and men must agree to use highly effective from signing of the informed consent form until at least 1 month after the last study drug administration. The investigator or a designated associate is requested to advise the patient how to achieve highly effective birth control (failure rate of less than 1% per year), e.g. hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner and sexual abstinence

Exclusion criteria

Exclusion Criteria:

Medical and surgical history:

  • Uncontrolled hypertension (Blood pressure ≥ 150/90 mmHg despite optimal medical management)
  • Proteinuria of grade 3 or higher (> 3.5 g/24 h, measured by urine protein: creatinine ratio on a random urine sample)
  • Known bleeding diathesis. Any hemorrhage or bleeding event ≥ Grade 3 within 28 days of start of study medication. (NCI-CTCAE Version 4.03)
  • Uncontrolled diabetes with ≥ 8.5%
  • Ongoing cytomegalovirus (CMV) infection as confirmed by positive polymerase chain reaction (PCR) for CMV

Excluded previous therapies and medications:

  • Prior treatment with PI3K inhibitors
  • Anticancer chemotherapy or immunotherapy during the study or within 28 days of first study treatment.
  • Patients must have recovered from the toxic effects (Grade \<2) of the previous anti-cancer chemotherapy or immunotherapy (with the exception of alopecia)
  • Biological response modifiers, such as Granulocyte colony stimulating factor (GCSF) within 14 days of first study treatment. G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the principal investigator; however they may not be substituted for a required dose reduction
  • Use of strong inhibitors of is prohibited from Day -14 and for the duration of the study
  • Use of St John's Wort or strong inducers of CYP3A4 is prohibited from Day -14 and for the duration of the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Copanlisib (Aliqopa, BAY80-6946)

    Planned at least 12 patients who meet the entry criteria will receive 60 mg copanlisib as single agent, with dosing on Days 1, 8 and 15 of each 28-day treatment cycle

    Drug: Copanlisib (Aliqopa, BAY80-6946)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Cycle 1 Day 1) of Copanlisib

    Cmax: maximum observed drug concentration in measured matrix after single dose administration

    Time frame: Pre-dose, 10 minutes, 1, 1.5, 2, 3, 5, 8, 11, 24, 48, 72, 120 and 168 hours after start of infusion

  2. AUC(0-24) (Cycle 1 Day 1) of Copanlisib

    AUC: area under the concentration vs. time curve from zero to infinity after single (first) dose

    Time frame: Pre-dose, 10 minutes, 1, 1.5, 2, 3, 5, 8, 11, 24, 48, 72, 120 and 168 hours after start of infusion

  3. AUC(0-tlast) (Cycle 1 Day 1) of Copanlisib

    Time frame: Pre-dose, 10 minutes, 1, 1.5, 2, 3, 5, 8, 11, 24, 48, 72, 120 and 168 hours after start of infusion

  4. Cmax (Cycle 1 Day 15) of Copanlisib

    Time frame: Pre-dose, 10 minutes, 1, 1.5, 2, 3, 5, 8, 11 and 24 hours after start of infusion

  5. AUC(0-24) (Cycle 1 Day 15) of Copanlisib

    Time frame: Pre-dose, 10 minutes, 1, 1.5, 2, 3, 5, 8, 11 and 24 hours after start of infusion

Secondary outcomes

  1. Overall response rate: proportion of patients with confirmed complete response (CR) and partial response (PR)

    Time frame: Up to about 6 months

  2. Overall disease control rate: proportion of patients who have a best response rating of CR, PR or stable disease (SD)

    Time frame: Up to about 6 months

  3. The number of serious drug-related TEAEs (treatment-emergent adverse events)

    Time frame: Up to about 7 months

  4. The number of non-serious drug-related TEAEs

    Time frame: Up to about 7 months

  5. Cmax (Cycle 1 Day 1) of M-1 metabolite

    Time frame: Pre-dose, 10 minutes, 1, 1.5, 2, 3, 5, 8, 11, 24, 48, 72, 120 and 168 hours after start of infusion

  6. AUC(0-24) (Cycle 1 Day 1) of M-1 metabolite

    Time frame: Pre-dose, 10 minutes, 1, 1.5, 2, 3, 5, 8, 11, 24, 48, 72, 120 and 168 hours after start of infusion

  7. AUC(0-tlast) (Cycle 1 Day 1) of M-1 metabolite

    Time frame: Pre-dose, 10 minutes, 1, 1.5, 2, 3, 5, 8, 11, 24, 48, 72, 120 and 168 hours after start of infusion

  8. Cmax (Cycle 1 Day 15) of M-1 metabolite

    Time frame: Pre-dose, 10 minutes, 1, 1.5, 2, 3, 5, 8, 11 and 24 hours after start of infusion

  9. AUC(0-24) (Cycle 1 Day 15) of M-1 metabolite

    Time frame: Pre-dose, 10 minutes, 1, 1.5, 2, 3, 5, 8, 11 and 24 hours after start of infusion

07

Study locations

1 site
  • Beijing Cancer Hospital
    Beijing, 100142, China
08

References and documents

Publications

  • Liu W, Ping L, Xie Y, Sun Y, Du T, Niu Y, Cisternas G, Huang F, Garcia-Vargas J, Childs BH, Mehra A, Reschke S, Wang X, Song Y, Zhu J. A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2022 Jun;89(6):825-831. doi: 10.1007/s00280-022-04417-3. Epub 2022 Mar 23. PubMed 35322287 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Aug 2019, 15 months.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's 15 months is below that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2018
First posted
Apr 13, 2018
StartActual
Apr 27, 2018
Primary completionActual
Aug 6, 2019
CompletionActual
Jun 2, 2020
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03498430
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 13, 2018
Start date
Apr 27, 2018
Primary completion
Aug 6, 2019
Completion
Jun 2, 2020
Last update
May 19, 2021

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Copanlisib

Start the discussion